Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Stock-Based Compensation history
Currency unavailable · from the cash flow
No Stock-Based Compensation data reported for this period type.
Stock-Based Compensation vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $50.3M USD | +35.9% | +74.2% | 55.6% | |
| LTM Jun 2026 | $49.82M USD | +13.3% | +23.8% | 17.7% | |
| LTM Mar 2026 | $41.12M USD | +24.3% | +9.7% | 17.7% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $36.4M USD | -7.4% | +94.0% | 492.0% |
| LTM Mar 2026 | $12.05M USD | -2.1% | -6.3% | 144.0% | |
| LTM Mar 2026 | $11.29M USD | +44.4% | +3.8% | — | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $9.13M USD | -54.6% | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ODTX) | — | +13.3% | +16.8% | 55.6% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.